Halozyme Therapeutics, Inc. (HALO) earnings: date, estimates, results and stock reactions
Next earnings: Q4 FY2026 on 2027-02-16 (expected, time not announced). EPS estimate 2.57, revenue estimate 551.4M.
Over the last 12 reports the stock moved 9.4% on average (either way), rising 9 times and falling 3. EPS beat estimates 10 of 12 times; revenue 6 of 12. Close before the report date to the first close after it (two trading sessions, covering before-the-open and after-the-close reports).
| Quarter | Reported | EPS | EPS estimate | EPS surprise | Revenue | Revenue estimate | Stock move |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-05 | 2.39 | 2.30 | +3.9% | 493.0M | 491.6M | -20.5% |
| Q2 FY2026 | 2026-08-06 | 2.28 | 1.79 | +27.4% | 481.0M | 402.3M | +23.4% |
| Q1 FY2026 | 2026-05-11 | 1.60 | 1.55 | +3.2% | 376.7M | 358.6M | +10.6% |
| Q4 FY2025 | 2026-02-17 | -0.24 | 2.15 | -111.2% | 451.8M | 435.7M | -7.8% |
| Q3 FY2025 | 2025-11-03 | 1.72 | 1.63 | +5.5% | 354.3M | 446.5M | +4.4% |
| Q2 FY2025 | 2025-08-05 | 1.54 | 1.23 | +25.2% | 325.7M | 330.8M | +3.9% |
| Q1 FY2025 | 2025-05-06 | 1.11 | 0.95 | +16.8% | 264.9M | 281.0M | +15.7% |
| Q4 FY2024 | 2025-02-18 | 1.26 | 1.17 | +7.7% | 298.0M | 285.7M | -0.9% |